Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Conditions:   Gastric Cancer;   Gastroesophageal Cancer Interventions:   Drug: KH903 + Paclitaxel;   Drug: Placebo + Paclitaxel Sponsor:   Chengdu Kanghong Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials